Chapter 12 Liposome-Mediated Therapy of Neuroblastoma

Methods in Enzymology

Volumn 465, Issue C, 2009, Pages 225-249

  Di Paolo, Daniela ^a,g   Loi, Monica ^a,g   Pastorino, Fabio ^a   Brignole, Chiara ^a   Marimpietri, Danilo ^a   Becherini, Pamela ^a   Caffa, Irene ^a   Zorzoli, Alessia ^a   Longhi, Renato ^b   Gagliani, Cristina ^c,d   Tacchetti, Carlo ^c,d   Corti, Angelo ^e   Allen, Theresa M ^f   Ponzoni, Mirco ^a   Pagnan, Gabriella ^a  

^a G GASLINI INSTITUTE   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f UNIVERSITY OF ALBERTA   (Canada)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DISTEAROYLGLYCERO 3 PHOSPHOETHANOLAMINE N [AMINO(POLYETHYLENE GLYCOL) 2000]; 1,2 DISTEAROYLGLYCERO 3 PHOSPHOETHANOLAMINE N [CARBOXY(POLYETHYLENE GLYCOL) 2000]; ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; DOXORUBICIN; FENRETINIDE; GOLD; GOLD NANOPARTICLE; IMMUNOLIPOSOME; LIPOSOME; MACROGOL 2000; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY GD2; OLIGONUCLEOTIDE; UNCLASSIFIED DRUG; GANGLIOSIDE; GANGLIOSIDE, GD2;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CELL PROLIFERATION; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG TARGETING; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION; HUMAN; LIPOSOMAL DELIVERY; MEDIATOR; NANOENCAPSULATION; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SURVIVAL TIME; TRANSMISSION ELECTRON MICROSCOPY; TUMOR GROWTH; TUMOR VASCULARIZATION; ANIMAL; ARTICLE; CANCER TRANSPLANTATION; CHEMISTRY; MOUSE; NEOVASCULARIZATION (PATHOLOGY); VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FENRETINIDE; GANGLIOSIDES; GOLD; LIPOSOMES; MICE; MICROSCOPY, ELECTRON, TRANSMISSION; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; NEUROBLASTOMA;

EID: 71849103407     PISSN: 00766879     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0076-6879(09)65012-6     Document Type: Review

References (105)

1. Adams G.P., and Weiner L.M. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23 (2005) 1147-1157
2. Agrawal S., and Iyer R.P. Perspectives in antisense therapeutics. Pharmacol. Ther. 76 (1997) 151-160
3. Alitalo K., Winqvist R., Lin C.C., de la Chapelle A., Schwab M., and Bishop J.M. Aberrant expression of an amplified c-myb oncogene in two cell lines from a colon carcinoma. Proc. Natl Acad. Sci. USA 81 (1984) 4534-4538
4. Allen T.M. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer 2 (2002) 750-763
5. Allen T.M., and Cullis P.R. Drug delivery systems: Entering the mainstream. Science 303 (2004) 1818-1822
6. Allen T.M., Hansen C., Martin F., Redemann C., and Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta 1066 (1991) 29-36
7. Allen T.M., Mehra T., Hansen C., and Chin Y.C. Stealth liposomes: An improved sustained release system for 1-beta-d-arabinofuranosylcytosine. Cancer Res. 52 (1992) 2431-2439
8. Allen T.M., Brandeis E., Hansen C.B., Kao G.Y., and Zalipsky S. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim. Biophys. Acta 1237 (1995) 99-108
9. Arap W., Pasqualini R., and Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279 (1998) 377-380
10. Arap W., Kolonin M.G., Trepel M., Lahdenranta J., Cardo-Vila M., Giordano R.J., Mintz P.J., Ardelt P.U., Yao V.J., Vidal C.I., Chen L., Flamm A., et al. Steps toward mapping the human vasculature by phage display. Nat. Med. 8 (2002) 121-127
11. Bagley R.G., Rouleau C., Morgenbesser S.D., Weber W., Cook B.P., Shankara S., Madden S.L., and Teicher B.A. Pericytes from human non-small cell lung carcinomas: An attractive target for anti-angiogenic therapy. Microvasc. Res. 71 (2006) 163-174
12. Beltinger C., Saragovi H.U., Smith R.M., LeSauteur L., Shah N., DeDionisio L., Christensen L., Raible A., Jarett L., and Gewirtz A.M. Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J. Clin. Invest. 95 (1995) 1814-1823
13. Bligh E.G., and Dyer W.J. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37 (1959) 911-917
14. Bolotin E.M., Cohen R., Bar L.K., Emanuel N., Ninio S., Lasic D.D., and Barenholz Y. Ammonium sulphate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes and ligandoliposomes. J. Liposmes Res. 4 (1994) 455-479
15. Brewer M., Kirkpatrick N.D., Wharton J.T., Wang J., Hatch K., Auersperg N., Utzinger U., Gershenson D., Bast R., and Zou C. 4-HPR modulates gene expression in ovarian cells. Int. J. Cancer 119 (2006) 1005-1013
16. Brignole C., Marimpietri D., Gambini C., Allen T.M., Ponzoni M., and Pastorino F. Development of Fab′ fragments of anti-GD(2) immunoliposomes entrapping doxorubicin for experimental therapy of human neuroblastoma. Cancer Lett. 197 (2003) 199-204
17. Brignole C., Pagnan G., Marimpietri D., Cosimo E., Allen T.M., Ponzoni M., and Pastorino F. Targeted delivery system for antisense oligonucleotides: A novel experimental strategy for neuroblastoma treatment. Cancer Lett. 197 (2003) 231-235
18. Brignole C., Pastorino F., Marimpietri D., Pagnan G., Pistorio A., Allen T.M., Pistoia V., and Ponzoni M. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs. J. Natl. Cancer Inst. 96 (2004) 1171-1180
19. Brignole C., Marimpietri D., Pagnan G., Di Paolo D., Zancolli M., Pistoia V., Ponzoni M., and Pastorino F. Neuroblastoma targeting by c-myb-selective antisense oligonucleotides entrapped in anti-GD2 immunoliposome: Immune cell-mediated anti-tumor activities. Cancer Lett. 228 (2005) 181-186
20. Broder H., Gottlieb R.A., and Lepor N.E. Chemotherapy and cardiotoxicity. Rev. Cardiovasc. Med. 9 (2008) 75-83
21. Brodeur G.M., and Maris J.M. Neuroblastoma (2006), J. B. Lippincott Company, Philadelphia
22. Carpentier A.F., Chen L., Maltonti F., and Delattre J.Y. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res. 59 (1999) 5429-5432
23. Chantrain C.F., Henriet P., Jodele S., Emonard H., Feron O., Courtoy P.J., DeClerck Y.A., and Marbaix E. Mechanisms of pericyte recruitment in tumour angiogenesis: A new role for metalloproteinases. Eur. J. Cancer 42 (2006) 310-318
24. Colombo G., Curnis F., De Mori G.M., Gasparri A., Longoni C., Sacchi A., Longhi R., and Corti A. Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif. J. Biol. Chem. 277 (2002) 47891-47897
25. Conte M., Parodi S., De Bernardi B., Milanaccio C., Mazzocco K., Angelini P., Viscardi E., Di Cataldo A., Luksch R., and Haupt R. Neuroblastoma in adolescents: The Italian experience. Cancer 106 (2006) 1409-1417
26. Corrias M.V., Guarnaccia F., and Ponzoni M. Bioavailability of antisense oligonucleotides in neuroblastoma cells: Comparison of efficacy among different types of molecules. J. Neurooncol. 31 (1997) 171-180
27. Crooke S.T. Progress in antisense therapeutics. Hematol. Pathol. 9 (1995) 59-72
28. Curnis F., Sacchi A., Borgna L., Magni F., Gasparri A., and Corti A. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat. Biotechnol. 18 (2000) 1185-1190
29. Curnis F., Arrigoni G., Sacchi A., Fischetti L., Arap W., Pasqualini R., and Corti A. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res. 62 (2002) 867-874
30. Curnis F., Sacchi A., and Corti A. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J. Clin. Invest. 110 (2002) 475-482
31. Curnis F., Sacchi A., Gasparri A., Longhi R., Bachi A., Doglioni C., Bordignon C., Traversari C., Rizzardi G.P., and Corti A. Isoaspartate-glycine-arginine: A new tumor vasculature-targeting motif. Cancer Res. 68 (2008) 7073-7082
32. De Bernardi B., Nicolas B., Boni L., Indolfi P., Carli M., Cordero Di Montezemolo L., Donfrancesco A., Pession A., Provenzi M., di Cataldo A., Rizzo A., Tonini G.P., et al. Disseminated neuroblastoma in children older than one year at diagnosis: Comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. J. Clin. Oncol. 21 (2003) 1592-1601
33. Di Matteo P., Curnis F., Longhi R., Colombo G., Sacchi A., Crippa L., Protti M.P., Ponzoni M., Toma S., and Corti A. Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif. Mol. Immunol. 43 (2006) 1509-1518
34. Ding L., Samuel J., MacLean G.D., Noujaim A.A., Diener E., and Longenecker B.M. Effective drug-antibody targeting using a novel monoclonal antibody against the proliferative compartment of mammalian squamous carcinomas. Cancer Immunol. Immunother. 32 (1990) 105-109
35. Ekwobi C.C. The prognostic value of c-myc oncoprotein levels in malignant melanoma. J. Plast. Reconstr. Aesthet. Surg. 61 (2008) 464
36. Ellerby H.M., Arap W., Ellerby L.M., Kain R., Andrusiak R., Rio G.D., Krajewski S., Lombardo C.R., Rao R., Ruoslahti E., Bredesen D.E., and Pasqualini R. Anti-cancer activity of targeted pro-apoptotic peptides. Nat. Med. 5 (1999) 1032-1038
37. Felgner P.L., and Rhodes G. Gene therapeutics. Nature 349 (1991) 351-352
38. Fidler I.J., and Ellis L.M. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79 (1994) 185-188
39. Folkman J. Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med. 285 (1971) 1182-1186
40. Frost J.D., Hank J.A., Reaman G.H., Frierdich S., Seeger R.C., Gan J., Anderson P.M., Ettinger L.J., Cairo M.S., Blazar B.R., Krailo M.D., Matthay K.K., et al. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: A report of the Children's Cancer Group. Cancer 80 (1997) 317-333
41. Gabizon A., Tzemach D., Mak L., Bronstein M., and Horowitz A.T. Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models. J. Drug Target. 10 (2002) 539-548
42. Galderisi U., Cascino A., and Giordano A. Antisense oligonucleotides as therapeutic agents. J. Cell. Physiol. 181 (1999) 251-257
43. Gutierrez-Puente Y., Tari A.M., Stephens C., Rosenblum M., Guerra R.T., and Lopez-Berestein G. Safety, pharmacokinetics, and tissue distribution of liposomal P-ethoxy antisense oligonucleotides targeted to Bcl-2. J. Pharmacol. Exp. Ther. 291 (1999) 865-869
44. Hamaguchi T., Matsumura Y., Nakanishi Y., Muro K., Yamada Y., Shimada Y., Shirao K., Niki H., Hosokawa S., Tagawa T., and Kakizoe T. Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts. Cancer Sci. 95 (2004) 608-613
45. Handley D.A., Arbeeny C.M., Witte L.D., and Chien S. Colloidal gold-Low density lipoprotein conjugates as membrane receptor probes. Proc. Natl. Acad. Sci. USA 78 (1981) 368-371
46. Hansen C.B., Kao G.Y., Moase E.H., Zalipsky S., and Allen T.M. Attachment of antibodies to sterically stabilized liposomes: Evaluation, comparison and optimization of coupling procedures. Biochim. Biophys. Acta 1239 (1995) 133-144
47. Hartmann G., and Krieg A.M. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J. Immunol. 164 (2000) 944-953
48. Henry S.P., Templin M.V., Gillett N., Rojko J., and Levin A.A. Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1. Toxicol. Pathol. 27 (1999) 95-100
49. Hillen F., and Griffioen A.W. Tumour vascularization: Sprouting angiogenesis and beyond. Cancer Metastasis Rev. 26 3-4 (2007) 489-502
50. Hong K., Friend D.S., Glabe C.G., and Papahadjopoulos D. Liposomes containing colloidal gold are a useful probe of liposome-cell interactions. Biochim. Biophys. Acta 732 (1983) 320-323
51. Hood J.D., Bednarski M., Frausto R., Guccione S., Reisfeld R.A., Xiang R., and Cheresh D.A. Tumor regression by targeted gene delivery to the neovasculature. Science 296 (2002) 2404-2407
52. Huwyler J., Wu D., and Pardridge W.M. Brain drug delivery of small molecules using immunoliposomes. Proc. Natl. Acad. Sci. USA 93 (1996) 14164-14169
53. Injac R., and Strukelj B. Recent advances in protection against doxorubicin-induced toxicity. Technol. Cancer Res. Treat. 7 (2008) 497-516
54. Ishida O., Maruyama K., Tanahashi H., Iwatsuru M., Sasaki K., Eriguchi M., and Yanagie H. Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo. Pharm. Res. 18 (2001) 1042-1048
55. Iversen P.L., Arora V., Acker A.J., Mason D.H., and Devi G.R. Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans. Clin. Cancer Res. 9 (2003) 2510-2519
56. Jin H., and Varner J. Integrins: Roles in cancer development and as treatment targets. Br. J. Cancer 90 (2004) 561-565
57. Kirpotin D.B., Drummond D.C., Shao Y., Shalaby M.R., Hong K., Nielsen U.B., Marks J.D., Benz C.C., and Park J.W. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 66 (2006) 6732-6740
58. Klinman D.M. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol. 4 (2004) 249-258
59. Kouhara J., Yoshida T., Nakata S., Horinaka M., Wakada M., Ueda Y., Yamagishi H., and Sakai T. Fenretinide up-regulates DR5/TRAIL-R2 expression via the induction of the transcription factor CHOP and combined treatment with fenretinide and TRAIL induces synergistic apoptosis in colon cancer cell lines. Int. J. Oncol. 30 (2007) 679-687
60. Kowalczyk A., Gil M., Horwacik I., Odrowaz Z., Kozbor D., and Rokita H. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells. Cancer Lett. 281 2 (2009) 171-182
61. Krieg A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5 (2006) 471-484
62. Kuefer R., Genze F., Zugmaier W., Hautmann R.E., Rinnab L., Gschwend J.E., Angelmeier M., Estrada A., and Buechele B. Antagonistic effects of sodium butyrate and N-(4-hydroxyphenyl)-retinamide on prostate cancer. Neoplasia 9 (2007) 246-253
63. Lopes de Menezes D.E., Pilarski L.M., and Allen T.M. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res. 58 (1998) 3320-3330
64. Mahabeleshwar G.H., Feng W., Reddy K., Plow E.F., and Byzova T.V. Mechanisms of integrin-vascular endothelial growth factor receptor cross-activation in angiogenesis. Circ. Res. 101 (2007) 570-580
65. Mannava S., Grachtchouk V., Wheeler L.J., Im M., Zhuang D., Slavina E.G., Mathews C.K., Shewach D.S., and Nikiforov M.A. Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells. Cell Cycle 7 (2008) 2392-2400
66. Marchio S., Lahdenranta J., Schlingemann R.O., Valdembri D., Wesseling P., Arap M.A., Hajitou A., Ozawa M.G., Trepel M., Giordano R.J., Nanus D.M., Dijkman H.B., et al. Aminopeptidase A is a functional target in angiogenic blood vessels. Cancer Cell 5 (2004) 151-162
67. Maris J.M., and Matthay K.K. Molecular biology of neuroblastoma. J. Clin. Oncol. 17 (1999) 2264-2279
68. Maris J.M., Hogarty M.D., Bagatell R., and Cohn S.L. Neuroblastoma. Lancet 369 (2007) 2106-2120
69. Matsumura Y., Gotoh M., Muro K., Yamada Y., Shirao K., Shimada Y., Okuwa M., Matsumoto S., Miyata Y., Ohkura H., Chin K., Baba S., et al. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann. Oncol. 15 (2004) 517-525
70. Miano M., Garaventa A., Pizzitola M.R., Piccolo M.S., Dallorso S., Villavecchia G.P., Bertolazzi C., Cabria M., and De Bernardi B. Megatherapy combining I(131) metaiodobenzylguanidine and high-dose chemotherapy with haematopoietic progenitor cell rescue for neuroblastoma. Bone Marrow Transplant. 27 (2001) 571-574
71. Moase E.H., Qi W., Ishida T., Gabos Z., Longenecker B.M., Zimmermann G.L., Ding L., Krantz M., and Allem T.M. Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer. Biochim. Biophys. Acta 77996 (2000) 1-13
72. Montaldo P.G., Pagnan G., Pastorino F., Chiesa V., Raffaghello L., Kirchmeier M., Allen T.M., and Ponzoni M. N-(4-hydroxyphenyl) retinamide is cytotoxic to melanoma cells in vitro through induction of programmed cell death. Int. J. Cancer 81 (1999) 262-267
73. Mui B., Raney S.G., Semple S.C., and Hope M.J. Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles. J. Pharmacol. Exp. Ther. 298 (2001) 1185-1192
74. Mujoo K., Cheresh D.A., Yang H.M., and Reisfeld R.A. Disialoganglioside GD2 on human neuroblastoma cells: Target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res. 47 (1987) 1098-1104
75. Niethammer A.G., Xiang R., Becker J.C., Wodrich H., Pertl U., Karsten G., Eliceiri B.P., and Reisfeld R.A. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat. Med. 8 (2002) 1369-1375
76. Pagnan G., Montaldo P.G., Pastorino F., Raffaghello L., Kirchmeier M., Allen T.M., and Ponzoni M. GD2-mediated melanoma cell targeting and cytotoxicity of liposome-entrapped fenretinide. Int. J. Cancer 81 (1999) 268-274
77. Pagnan G., Stuart D.D., Pastorino F., Raffaghello L., Montaldo P.G., Allen T.M., Calabretta B., and Ponzoni M. Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD(2)-targeted immunoliposomes: Antitumor effects. J. Natl. Cancer Inst. 92 (2000) 253-261
78. Park J.W., Hong K., Carter P., Asgari H., Guo L.Y., Keller G.A., Wirth C., Shalaby R., Kotts C., Wood W.I., et al. Development of anti-p185HER2 immunoliposomes for cancer therapy. Proc. Natl. Acad. Sci. USA 92 (1995) 1327-1331
79. Pasqualini R., Koivunen E., Kain R., Lahdenranta J., Sakamoto M., Stryhn A., Ashmun R.A., Shapiro L.H., Arap W., and Ruoslahti E. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 60 (2000) 722-727
80. Pastorino F., Stuart D., Ponzoni M., and Allen T.M. Targeted delivery of antisense oligonucleotides in cancer. J. Control Release 74 (2001) 69-75
81. Pastorino F., Brignole C., Marimpietri D., Cilli M., Gambini C., Ribatti D., Longhi R., Allen T.M., Corti A., and Ponzoni M. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res. 63 (2003) 7400-7409
82. Pastorino F., Brignole C., Marimpietri D., Sapra P., Moase E.H., Allen T.M., and Ponzoni M. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res. 63 (2003) 86-92
83. Pastorino F., Brignole C., Di Paolo D., Nico B., Pezzolo A., Marimpietri D., Pagnan G., Piccardi F., Cilli M., Longhi R., Ribatti D., Corti A., et al. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res. 66 (2006) 10073-10082
84. Pastorino F., Marimpietri D., Brignole C., Di Paolo D., Pagnan G., Daga A., Piccardi F., Cilli M., Allen T.M., and Ponzoni M. Ligand-targeted liposomal therapies of Neuroblastoma. Curr. Med. Chem. 14 29 (2007) 3070-3078
85. Pastorino F., Di Paolo D., Piccardi F., Nico B., Ribatti D., Daga A., Baio G., Neumaier C.E., Brignole C., Loi M., Marimpietri D., Pagnan G., et al. Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin. Clin. Cancer Res. 14 (2008) 7320-7329
86. Ponzoni M., Bocca P., Chiesa V., Decensi A., Pistoia V., Raffaghello L., Rozzo C., and Montaldo P.G. Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: Apoptosis versus differentiation. Cancer Res. 55 (1995) 853-861
87. Raffaghello L., Pagnan G., Pastorino F., Cosimo E., Brignole C., Marimpietri D., Bogenmann E., Ponzoni M., and Montaldo P.G. Immunoliposomal fenretinide: A novel antitumoral drug for human neuroblastoma. Cancer Lett. 197 (2003) 151-155
88. Raffaghello L., Pagnan G., Pastorino F., Cosimo E., Brignole C., Marimpietri D., Montaldo P.G., Gambini C., Allen T.M., Bogenmann E., and Ponzoni M. In vitro and in vivo antitumor activity of liposomal fenretinide targeted to human neuroblastoma. Int. J. Cancer 104 (2003) 559-567
89. Raschella G., Negroni A., Skorski T., Pucci S., Nieborowska-Skorska M., Romeo A., and Calabretta B. Inhibition of proliferation by c-myb antisense RNA and oligodeoxynucleotides in transformed neuroectodermal cell lines. Cancer Res. 52 (1992) 4221-4226
90. Ribatti D., Surico G., Vacca A., De Leonardis F., Lastilla G., Montaldo P.G., Rigillo N., and Ponzoni M. Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with progression in human neuroblastoma. Life Sci. 68 (2001) 1161-1168
91. Schulz G., Cheresh D.A., Varki N.M., Yu A., Staffileno L.K., and Reisfeld R.A. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res. 44 (1984) 5914-5920
92. Shishodia S., Harikumar K.B., Dass S., Ramawat K.G., and Aggarwal B.B. The guggul for chronic diseases: Ancient medicine, modern targets. Anticancer Res. 28 (2008) 3647-3664
93. Sipkins D.A., Cheresh D.A., Kazemi M.R., Nevin L.M., Bednarski M.D., and Li K.C. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat. Med. 4 (1998) 623-626
94. Stein C.A., and Cheng Y.C. Antisense oligonucleotides as therapeutic agents-Is the bullet really magical?. Science 261 (1993) 1004-1012
95. Stuart D.D., and Allen T.M. A new liposomal formulation for antisense oligodeoxynucleotides with small size, high incorporation efficiency and good stability. Biochim. Biophys. Acta 1463 (2000) 219-229
96. Sugano M., Egilmez N.K., Yokota S.J., Chen F.A., Harding J., Huang S.K., and Bankert R.B. Antibody targeting of doxorubicin-loaded liposomes suppresses the growth and metastatic spread of established human lung tumor xenografts in severe combined immunodeficient mice. Cancer Res. 60 (2000) 6942-6949
97. Tamm I. Antisense therapy in clinical oncology: Preclinical and clinical experiences. Methods Mol. Med. 106 (2005) 113-134
98. Tamm I., Dorken B., and Hartmann G. Antisense therapy in oncology: New hope for an old idea?. Lancet 358 (2001) 489-497
99. Torchilin V.P. Application of nanomedical approaches in experimental and clinical oncology. Anticancer Agents Med. Chem. 6 (2006) 501
100. Trepel M., Arap W., and Pasqualini R. In vivo phage display and vascular heterogeneity: Implications for targeted medicine. Curr. Opin. Chem. Biol. 6 (2002) 399-404
101. Uttenreuther-Fischer M.M., Huang C.S., Reisfeld R.A., and Yu A.L. Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a phase I trial in pediatric cancer patients. Cancer Immunol. Immunother. 41 (1995) 29-36
102. von Allmen D., Grupp S., Diller L., Marcus K., Ecklund K., Meyer J., and Shamberger R.C. Aggressive surgical therapy and radiotherapy for patients with high-risk neuroblastoma treated with rapid sequence tandem transplant. J. Pediatr. Surg. 40 (2005) 936-941 discussion: 941
103. Wagner R.W. The state of the art in antisense research. Nat. Med. 1 (1995) 1116-1118
104. Wei J.S., Whiteford C.C., Cenacchi N., Son C.G., and Khan J. BBC3 mediates fenretinide-induced cell death in neuroblastoma. Oncogene 24 (2005) 7976-7983
105. Zurita A.J., Arap W., and Pasqualini R. Mapping tumor vascular diversity by screening phage display libraries. J. Control Release 91 (2003) 183-186